One Health Ventures (OHV) is an early-stage company developing a proprietary, recombinant, genetic toxoid vaccine against epsilon toxin (ETX). Produced from a common bacteria Clostridium perfringens Types B/D, ETX causes enterotoxaemia, a fatal disease in sheep and goats. ETX has also been implicated in Multiple Sclerosis (MS), which affects 2.5 million people worldwide and for which there is currently no cure. Levels of ETX, antibodies to ETX and relevant bacterial strains are significantly higher in MS patients compared to healthy controls. OHV seeks a commercial partner(s) to help advance the program into clinic as novel vaccine for MS in humans.